IngredientsThe term ravinsara — also rendered in commercial and aromatherapy literature as ravintsara or, erroneously, ravensara — refers to the cineole-rich chemotype of the camphor tree, Cinnamomum camphora (L.) J. Presl, belonging to the family Lauraceae. Ravintsara's botanical name is Cinnamomum camphora CT cineole (Madagascar), and it belongs to the Lauraceae family. The designation "CT" (chemotype) is critical: according to the type and content of main components in the volatile leaf oil, C. camphora is divided into five chemotypes, including borneol-type, camphor-type, linalool-type, cineole-type, and nerolidol-type. It is the cineole-type chemotype — the one that predominates in Madagascar — that is commercially traded as ravintsara or ravinsara.
The taxonomic and commercial confusion surrounding this material is substantial and well-documented in the peer-reviewed literature. The commercial and identical Malagasy denominations of ravintsara and ravensara essential oils have generated confusion in the marketplace. The essential oil of ravintsara is obtained from the leaves of Cinnamomum camphora, which was introduced from Taiwan and now grows widely in Madagascar. This essential oil has been misreported and traded as ravensara, botanically classified as Ravensara aromatica. These are fundamentally different plants: the true ravensara (R. aromatica) essential oil is extracted from the leaves of an endemic species locally known as "havozo" or "hazomanitra," meaning "aromatic tree" in the Malagasy language. This species was also described under the botanical names R. anisata Danguy and Agathophyllum aromaticum Willd. However, R. aromatica Sonn. is the correct botanical name and has precedence over these synonyms.
The taxonomical confusion, translation similarities of the common names, and the lack of regional, national and international quality standards continue to allow the misidentification of these oils in the marketplace. The name "ravinsara" itself, without the "t," is effectively a further corruption: in the first case, this is probably due to the fact that "ravinsara" recalls the pronunciation of the Latin name for ravensare (Ravensara aromatica). In the second case, the confusion between the two terms can be explained by their similarity in spelling, since there is only one "t" between them. To avoid any confusion, it is best to avoid using the word "ravinsara," which is likely to mislead.
The etymological root of the name is Malagasy: in Malagasy, "ravina" and "tsara" mean "good leaf." Remarkably, the botanical name of the genus Ravensara itself came from the Latinisation of the Malagasy word "ravintsara" (meaning "good leaves"), which refers to the introduced species C. camphora. This etymological irony — that the genus name Ravensara was derived from the Malagasy common name for the unrelated C. camphora — is a primary driver of the ongoing commercial and scientific confusion.
In the scientific literature and in authenticated aromatherapy commerce, the correct and preferred spelling is ravintsara, referring specifically to the Madagascar cineole chemotype of Cinnamomum camphora. The spelling "ravinsara" (without the internal "t") appears primarily as a commercial or typographic variant in European markets and should be understood as synonymous with ravintsara in the context of this article. It is often a spelling confusion, but ravintsara (Cinnamomum camphora) is the correct name for this antiviral essential oil, whereas ravinsara is a clerical error.
The plant from which ravintsara essential oil is extracted (Cinnamomum camphora sb 1,8-cineole) is a camphor tree in the Lauraceae family, which also includes the European species of laurel. It can reach 25 metres in height, and has thick leaves that can be recognised by the camphor odour they give off when crumpled. It is these leaves that are distilled to produce ravintsara essential oil.
Originally from China and Japan, the camphor tree has adapted perfectly to Madagascar's climate. This is why Madagascar is the main distillation site for this essential oil. More precisely, the essential oil of ravintsara is obtained from the leaves of a tree (Cinnamomum camphora (L.) J. Presl), which was introduced from Taiwan as an ornamental tree and now grows widely in Madagascar, with increased demand from the international market.
The camphor tree is an ecologically flexible species. Camphor tree (Cinnamomum camphora) is an ornamental plant that has been cultivated for a long time to obtain wood or camphor. Furthermore, its essential oil can be used as an alternative medicine and is an important source of perfume. Within Madagascar, the ravintsara tree is cultivated primarily in the central highlands. As a member of the Lauraceae family, ravintsara has the botanical name Cinnamomum camphora and is an evergreen tree. It is present in the highland, in the centre of the island and on the coasts.
A defining feature of ravintsara as a distinct commercial and medicinal entity is the dramatic shift in its chemical composition following its introduction to Madagascar. Cinnamomum camphora was originally brought to Madagascar by the Chinese, but over time the synthesis of its essence changed, with 1,8-cineole (= eucalyptole) being added to the detriment of camphor. Thus, whereas the Asian tree reliably produces a camphor-rich oil, the ravintsara of Madagascar is a camphor tree that — notably — does not produce camphor. Instead, it produces 1,8-cineole, which gives it its specific character.
Five chemotypes — the isoborneol-type, camphora-type, cineole-type, linalool-type and borneol-type — of Cinnamomum camphora (L.) Presl have been identified at the molecular level based on the multivariate analysis of mass spectral fingerprints recorded from a total of 750 raw leaf samples. It is widely known that the different medicinal properties of these five C. camphora chemotypes arise from the diversity of their chemical composition.
Ravintsara is primarily available as an essential oil produced by steam distillation of the fresh or partially dried leaves. Ravintsara essential oil is extracted from the leaves of the tree. Distillation is performed at the harvesting site. The leaves are left to dry from a few hours up to 48 hours. They are then distilled for around two to three hours. To obtain one litre of essential oil, 125 kg of leaves need to be distilled. The oil yield from fresh weight has been reported in similar C. camphora preparations at approximately 0.6–1.11% by weight. The yield is 0.7 to 1%. The essential oil is a limpid, colourless to pale yellow liquid with a fresh, cineole-like odour reminiscent of eucalyptus. The density is 0.905–0.920 at 20 °C.
Beyond the distilled essential oil, ravintsara also occurs in traditional use as a hydrosol (aromatic water remaining after distillation), as dried leaf infusions (herbal teas), and as a crude leaf preparation. The chemical compositions of ravintsara (Cinnamomum camphora (L.) Presl) essential oil and aromatic fraction of hydrolat were determined by gas chromatography. Six compounds were identified for the first time in this essential oil: linalool, para-menth-2-en-1-ol, δ-terpineol, borneol, trans-nerolidol and globulol. Thirteen compounds are identified in the aromatic fraction of ravintsara hydrolat, representing more than 90% of the product. 1,8-Cineole is the major component of both essential oil and hydrolat. Traditional leaf preparations exist as well: traditionally, ravintsara has been used in Madagascar for its medicinal properties, treating ailments such as colds, flu, and herpes. The local population values the dried leaves for tea and chewing to strengthen the immune system.
In aromatherapy practice, the essential oil is applied by atmospheric diffusion, topical application (generally diluted in a carrier oil), and steam inhalation. Oral forms of the primary active constituent, 1,8-cineole, have been studied clinically in enteric-coated capsules (Soledum™) at standardised doses, though these are eucalyptus-derived pharmaceutical products rather than ravintsara-specific preparations. In Germany, Soledum™ enteric-coated capsules, which contain 100 mg or 200 mg (forte) of 1,8-cineole (CNL-1976) per capsule, have been registered as authorised medicinal products for several years and are utilised in treating inflammatory respiratory disorders such as the common cold, bronchitis, sinusitis, bronchial asthma, and COPD.
The documented history of ravintsara use in Madagascar extends to at least the mid-seventeenth century. In his 1658 book Histoire de la grande île Madagascar, French commander Étienne de Flacourt noted the widespread use of ravintsara as a traditional remedy by the local population. The Malagasy people's use of the tree appears to predate European documentation: in Madagascar, Cinnamomum camphora is called ravintsara, meaning "good leaf" in Malagasy. This evergreen tree is native to East Asia and has been cultivated in Madagascar since the mid-19th century (and, per some accounts, was introduced considerably earlier). In his book published in 1658, French commander Étienne de Flacourt observed a massive use of ravintsara by the Malagasy population as a traditional remedy. Ravintsara essential oil was not extracted for the first time until a century later, in 1775, by the pharmacist and chemist Antoine Baumé.
Formally, in 1957, Pernet and Meyer in La pharmacopée de Madagascar recorded the use of the leaves of Cinnamomum camphora in cases of fever and malaria.
Traditional Malagasy preparations and uses include:
The purposes for which ravintsara was traditionally employed broadly correspond to respiratory infections, fevers, and immune support. Traditionally, ravintsara has been used in Madagascar for its medicinal properties, treating ailments such as colds, flu, and herpes.
The wider camphor tree (Cinnamomum camphora) has an ancient record of medicinal use across East Asia: camphor obtained from camphor trees has long been used as a treatment for various symptoms such as inflammation, infection, congestion, muscle pain, and irritation in various regions. The cineole-rich Madagascar chemotype, however, is a later-emerging distinct entity with its own specific ethnomedical record primarily within Madagascar. The essential oil did not become widespread in Western aromatherapy until after the 1980s.
The essential oil of ravintsara (Madagascar cineole-type C. camphora) is dominated by a small number of terpene compounds. Authenticated commercial samples have been characterized by gas chromatography-mass spectrometry (GC-MS):
The essential oil of ravintsara (C. camphora) is typically colourless with fresh (1,8-cineole-type) and slightly spicy notes. The density is 0.908, the refractive index 1.4666, and optical rotation −16.6.
The broader phytochemical picture of C. camphora across all chemotypes includes: camphor, cineole, limonene, alpha-pinene, linalool, borneol, safrole, and nerolidol, with anti-inflammatory, antibacterial, anxiolytic, analgesic, immunomodulatory, antihyperlipidemic and many other pharmacological properties established in vitro or in vivo preclinical research. Importantly for product authentication and safety, Tisserand and Young report that oil sourced from China may contain safrole and methyleugenol, compounds with genotoxic potential; this underscores the importance of verifying geographic origin and chemotype when assessing the safety of any C. camphora oil.
The pharmacological actions attributed to ravintsara are, from a mechanistic standpoint, primarily the actions of its dominant constituent, 1,8-cineole (eucalyptol). The following mechanisms are those for which peer-reviewed evidence exists:
Evidence indicates that 1,8-cineole effectively modulates inflammatory pathways by inhibiting cytokine release and suppressing arachidonic acid metabolism. At the cellular level, 1,8-cineole was found to reduce the expression of NF-κB p65, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1 in lung tissues in murine influenza models. Many recent studies help to better understand the cellular and molecular immunological consequences of 1,8-cineole treatment in inflammatory diseases and further provide information concerning the mechanistic modes of action in the regulation of distinct inflammatory biosynthetic pathways.
1,8-cineole is a major monoterpene that has been shown to exert anti-inflammatory, antiviral, and inhibitory effects on nuclear factor (NF)-κB. In animal models of influenza, 1,8-cineole was found to protect against influenza viral infection in mice. Moreover, it efficiently decreased the levels of IL-4, IL-5, IL-10, and MCP-1 in nasal lavage fluids and the levels of IL-1β, IL-6, TNF-α, and IFN-γ in lung tissues of mice infected with influenza virus. The broader antimicrobial potential of 1,8-cineole is well-established: its anti-microbial potential and even its anti-viral effects have been observed to include numerous bacteria and fungi species.
Similar to other aromatic oils, 1,8-cineole is commonly used to treat respiratory tract infections due to its ability to increase the ciliary beat frequency in the mucus membrane and its bronchodilating and anti-inflammatory properties, as evidenced by preclinical studies.
1,8-cineole exhibits pharmacological activities by modulating the nuclear pathway, reducing the synthesis of reactive oxygen species (ROS), and promoting anti-inflammatory and antioxidant properties.
After oral administration, 1,8-cineole is absorbed in the small intestine and subsequently metabolised in the liver by human cytochrome P450 enzymes (CYP3A4/5). Its primary metabolites, 2α-hydroxy- and 3α-hydroxy-1,8-cineole, are excreted through urine. Systemic distribution is rapid: a rat pharmacokinetic study showed that the serum concentration time profiles of 1,8-cineole indicated that the absorption characteristics after an oral administration are similar compared to an intravenous administration. Following oral administration, the compound distributes to mucosal tissues: different 1,8-cineole-containing medications are known to be applied orally as enteric-coated capsules. It has recently been shown that 1,8-cineole was detectable in nasal tissue samples after its oral administration for 14 days, which indicates the systemic distribution of 1,8-cineole via the gut and the blood stream.
An important caveat applies throughout this section: Dedicated clinical trials of ravintsara essential oil (C. camphora CT cineole) as a whole-oil preparation are very limited. The bulk of available clinical evidence relates to its primary constituent, 1,8-cineole (eucalyptol), studied as an isolated, standardized pharmaceutical-grade compound in oral enteric-coated capsule form. Extrapolating these findings directly to the inhaled or topically applied whole essential oil of ravintsara must be done with caution, as dosing, bioavailability, and the potential synergistic or additive effects of minor constituents differ between the whole oil and the isolated compound.
This is the best-researched area for 1,8-cineole, with multiple randomised controlled trials conducted using the pharmaceutical preparation CNL-1976 (Soledum™ capsules). The efficacy of 1,8-cineole (Soledum™ capsules; CNL-1976) has been explored in clinical trials for a range of respiratory disorders, including acute rhinosinusitis, COPD, asthma, acute bronchitis, and the common cold.
Placebo-controlled double-blind trials impressively showed the beneficial anti-inflammatory activity of 1,8-cineol for treating inflammatory diseases, as in rhinosinusitis, bronchial asthma, and COPD. A comprehensive review concluded: clinical evidence has shown that 1,8-cineole provides symptom relief, improves lung function, and enhances quality of life, particularly in patients with COPD, asthma, and chronic sinusitis.
Key individual trial findings include:
Clinical trials demonstrate the efficacy of 1,8-cineole in reducing symptoms of chronic sinusitis, improving pulmonary function in asthma, and alleviating symptoms in upper respiratory tract infections. Due to its good safety profile and minimal side effects, it represents a very attractive adjunctive treatment option.
Evidence strength: For 1,8-cineole in the above respiratory conditions, the evidence from randomised, placebo-controlled clinical trials is moderately strong, supporting the use of standardised oral cineole preparations as adjunctive treatments. However, these trials used the isolated compound in enteric-coated capsules. No large-scale randomised clinical trials have been published specifically evaluating ravintsara essential oil as a whole preparation for these respiratory conditions.
In vitro and animal research provides mechanistic and preliminary evidence for antiviral activity. At the cellular level, the mechanisms of 1,8-cineole against influenza are well-characterised in animal research: 1,8-cineole appears to be able to augment protection against influenza virus infection in mice via attenuation of pulmonary inflammatory responses. A broader review of antimicrobial actions notes: an important aspect of natural anti-microbial compounds is the lower risk of antibiotic resistance development.
For the whole ravintsara oil specifically, a two-year exploratory study in a French hospital setting provided preliminary evidence. The essential oil of Cinnamomum camphora with cineole (ravintsara) is empirically known for its antiviral and immunostimulatory properties. In a preliminary trial, the oil's properties were studied to determine its effect on reducing nosocomial infections in a hospital setting. The results of the two-year trial are promising, but must be confirmed. This study was published in the French journal Phytothérapie in 2007 and must be categorised as preliminary and uncontrolled in design.
Evidence strength: Antiviral activity of 1,8-cineole against influenza is supported by preclinical (animal and cell-culture) evidence only. Specific clinical evidence for ravintsara essential oil as an antiviral agent in humans is limited to a single preliminary, uncontrolled institutional trial. No randomised controlled trials have been published specifically on ravintsara essential oil's antiviral efficacy in human subjects. Claims of antiviral potency in clinical aromatherapy literature substantially outrun the available controlled evidence.
The herbal potential of C. camphora is recognised to serve as an antibiotic, antiviral, and antifungal. In vitro studies have explored the antibacterial properties of C. camphora essential oils against clinical isolates, including drug-resistant strains. One study aimed to analyse the components of C. camphora grown in Saudi Arabia using GC-MS and to evaluate the in vitro antibacterial properties against certain clinical bacteria obtained from hospitals, including multi-drug resistant pathogens. The obtained MICs and MBCs verified the clinical strains' significant susceptibility to C. camphora essential oil. The development of E. coli biofilms is intimately associated with prolonged infection and can lead to antibiotic resistance. E. coli was significantly destroyed by the essential oil.
Evidence strength: Antibacterial activity of C. camphora essential oils (inclusive of the cineole chemotype) is supported by in vitro data only. No clinical trials in human subjects have specifically evaluated ravintsara essential oil for antibacterial endpoints. In vitro MIC data cannot be directly extrapolated to human clinical efficacy.
A specific mechanistic study using a human ex vivo model investigated the effect of 1,8-cineole on mucus production. Medical treatment of inflammatory diseases of the human respiratory tract may involve 1,8-cineol, the active ingredient of the clinically-accredited medical product Soledum. 1,8-cineol was identified in the 1870s as the major constituent of Eucalyptus globulus essential oil and possesses both anti-microbial and anti-inflammatory properties. Despite promising findings, a direct linkage between the anti-inflammatory activity of 1,8-cineol and mucus production as a hallmark of inflammatory diseases remains undetermined.
Evidence strength: Mucolytic and anti-mucus production effects of 1,8-cineole are supported by an ex vivo human tissue model. This is more mechanistically informative than animal data alone but does not constitute a clinical efficacy trial.
Preclinical studies have explored antioxidant and hepatoprotective properties. 1,8-cineole prevented an increase in malondialdehyde level, a decrease in glutathione level, and a decrease in the activity of superoxide dismutase and glutathione peroxidase enzymes in the liver of rats treated with lead acetate. This monoterpene also prevented an increase in the expression of pro-inflammatory cytokines and significantly reduced the infiltration of inflammatory cells in the liver parenchyma. Additionally, 1,8-cineole discouraged the increase in toll-like receptor 4 (TLR4), myeloid differentiation primary response 88 (MyD88), and nuclear factor kappa B (NF-κB) expression in the liver.
Evidence strength: Antioxidant and hepatoprotective effects of 1,8-cineole are supported by preclinical (animal) data only. No human clinical trials exist for these endpoints in the context of ravintsara or isolated 1,8-cineole.
Preclinical research in animal models of colitis has examined the effects of 1,8-cineole. When compared to vehicle-treated controls, a marked reduction in gross damage scores and wet weights of colonic segments was evident in animals pre-treated with 1,8-cineole. Cineole also significantly reduced myeloperoxidase activity and caused repletion of glutathione. These results confirm the anti-inflammatory action of 1,8-cineole and suggest its potential value as a dietary flavouring agent in the prevention of gastrointestinal inflammation and ulceration.
Evidence strength: Gastrointestinal anti-inflammatory effects are supported by animal (preclinical) data only. No human clinical trials exist.
Based on the available evidence (ranging from traditional use records to clinical trials of the constituent 1,8-cineole), ravintsara is primarily associated with the following body systems:
The following dosage information is drawn from published sources and refers either to the whole ravintsara essential oil as used in traditional and clinical settings, or to the primary constituent 1,8-cineole as used in clinical trials. No standardised therapeutic dose for ravintsara whole essential oil has been established in a clinical trial setting.
In Germany, Soledum™ enteric-coated capsules contain 100 mg or 200 mg (forte) of 1,8-cineole (CNL-1976) per capsule and are registered as authorised medicinal products. Clinical trials evaluating this preparation in respiratory conditions have generally employed dosing regimens of three times daily (t.i.d.) schedules. In related studies, the administration of 1,8-cineole has been investigated through oral or inhalation routes, employing different administration and dosage forms for various diseases.
In aromatherapy practice, diffusion of ravintsara essential oil is commonly employed. Sources reference 5 to 10 drops in a diffuser, with usage sessions typically not exceeding 30 minutes continuously to avoid olfactory saturation.
Ravintsara essential oil is routinely applied topically in aromatherapy, diluted in a vegetable carrier oil. Application sites reported in the literature include the chest, the soles of the feet, and the wrists. Ravintsara essential oil is commonly applied to the feet or wrists. This method of use ensures optimum penetration of the oil into the skin, as these are areas where the skin is normally thinner, well vascularised and not very sensitive. The specific percentage dilutions recommended in aromatherapy practice (e.g. 2–5% in carrier oil for adults) have not been established by controlled clinical trials.
Traditional use in Madagascar involves boiling leaves in water and inhaling the steam. Ultrasonic atomisation, nasal drops, and smears have been employed for the management of conditions such as COPD, asthma, anxiety, sinusitis, and inflammatory skin disorders in various research and clinical contexts for cineole-containing preparations generally.
The oral acute LD50 value of 1,8-cineole in rats is documented at 2480 mg/kg body weight. Repeated-dose studies provide further context: in the repeated-doses toxicity study for 50 days, 1,8-cineole (100, 500 or 1000 mg/kg) did not produce any signs of toxicity or deaths, but affected body weight gain during the first week of treatment. At therapeutic doses in human clinical trials, clinical evidence has shown that 1,8-cineole provides symptom relief, improves lung function, and enhances quality of life, particularly in patients with COPD, asthma, and chronic sinusitis. Due to its good safety profile and minimal side effects, it represents a very attractive adjunctive treatment option.
Overdosage is a distinct concern: while considered safe and well-tolerated at normal therapeutic doses, excessive use and overdosage of 1,8-cineole through oral ingestion, inhalation, or skin application can be hazardous and lead to potential acute toxicity, including inflammatory gastrointestinal conditions and rare symptoms like nausea, vomiting, and diarrhoea.
The paediatric safety of cineole-rich essential oils is a well-documented concern in the essential oil safety literature. Tisserand and Young state that "essential oils high in 1,8-cineole can cause CNS [central nervous system] and breathing problems in young children." They also caution not to use topically near the face of babies and children. This is a direct, source-documented safety concern and not merely a general precaution: the mechanism involves the capacity of 1,8-cineole to cause reflex apnoea in infants if applied close to the face or nose.
Preclinical data indicate that 1,8-cineole has reproductive safety concerns at high doses: cineole presents maternal and fetal toxicity in pre-implantation or organogenesis stages in animal models. This finding, combined with a general absence of human reproductive safety data, forms the basis for widespread caution regarding use during pregnancy.
Given that 1,8-cineole is a monoterpene with CNS activity, caution has been indicated for individuals with epilepsy or seizure disorders, although robust clinical data specifically characterising seizure risk from ravintsara/1,8-cineole at normal aromatherapy doses are not available in the peer-reviewed literature.
The CYP3A4/5-mediated hepatic metabolism of 1,8-cineole carries theoretical drug interaction potential. After oral administration, 1,8-cineole is absorbed in the small intestine and subsequently metabolised in the liver by human cytochrome P450 enzymes (CYP3A4/5). CYP3A4 is the primary enzyme involved in 1,8-cineole hydroxylation, and 1,8-cineole has been shown to interact with related monoterpene cineole substrates at the CYP3A level. Theoretical interactions with co-administered drugs that are CYP3A4 substrates (e.g. certain statins, immunosuppressants, antiretrovirals) exist, though the clinical magnitude of such interactions at the doses achieved through aromatherapy inhalation or topical use is unknown and has not been formally evaluated in human pharmacokinetic studies of the whole ravintsara oil.
The essential oils of ravensara and ravintsara are frequently misidentified in the marketplace, through a confusion that appears to have originated years ago. The practical safety consequence is that a bottle labelled "ravinsara" or "ravensara" may contain either the relatively well-characterised ravintsara (C. camphora CT cineole) or the chemically distinct ravensara (R. aromatica), with different constituent profiles and different risk-benefit considerations. The taxonomical confusion, translation similarities of the common names, and the lack of regional, national and international quality standards continue to allow the misidentification of these oils in the marketplace. GC-MS fingerprinting is the only reliable method of authentication.
Tisserand and Young report that oil sourced from China may contain safrole and methyleugenol, both of which are associated with genotoxicity at sufficient exposures. This underscores the importance of confirming that any C. camphora product labelled as ravintsara is confirmed by GC-MS to be of the cineole chemotype from Madagascar, free from these contaminants.
Ravintsara (Cinnamomum camphora CT cineole, Madagascar) sits at an intersection between a well-characterised traditional Malagasy medicinal plant and a partially evidence-supported aromatherapy essential oil. The weight of published clinical research supports the physiological activity of its primary constituent, 1,8-cineole, particularly in respiratory conditions. However, the following research gaps are notable:
Despite many studies focused on the essential oil of the camphor tree, there is a lack of systematic studies of its extraction or separation. Besides, various components of camphor are not fully understood, and further research is needed on the medicinal effects of individual components of C. camphora.
Health conditions that Ravinsara may help support.
Body systems that Ravinsara may help support.
Go back